Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

New research shows modifying noncoding RNA with N6-methyladenosine allows the RNA exosome to recognize a specific noncoding RNA associated with the genomic site that encodes the heavy chain of ...

A research team from National Taiwan University, Academia Sinica, and National Taiwan University Hospital has uncovered a critical connection between a unique RNA molecule and human aging ...

Strand Therapeutics has added to its series A funding from last year, bringing the total to $97 million. The messenger RNA (mRNA) therapeutics company is gearing up to bring its lead drug ...